Antibody-Drug Conjugate Combo Delivers 92.6% Complete Response Rate in Low-Risk Lymphoma Patients
A multicenter Chinese real-world study found that the antibody-drug conjugate regimen Pola-R-CHP achieved a 92.6 percent complete response rate in ...
Tag: novel therapies for non-Hodgkin lymphoma
-
Mothers who receive childcare support from maternal grandparents show more parental warmth, finds NTU Singapore study
-
University of Seville Breaks 120-Year-Old Mystery, Revises a Key Einstein Concept
-
Bee body mass, pathogens and local climate influence heat tolerance
-
Researchers record first-ever images and data of a shark experiencing a boat strike
-
Groundbreaking Clinical Trial Reveals Lubiprostone Enhances Kidney Function
Embark on a thrilling journey of discovery with Scienmag.com—your ultimate source for cutting-edge breakthroughs. Immerse yourself in a world where curiosity knows no limits and tomorrow’s possibilities become today’s reality!